Rosuvastatin and Dual Antiplatelet: Therapy Insights from Clinical Practice



INTRODUCTION

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, accounting for nearly 17.9 million deaths annually, a figure that continues to rise due to aging populations and increasing prevalence of risk factors such as obesity, diabetes, and hypertension (1). These diseases place immense pressure on healthcare systems, contributing to significant economic and social burdens (2). Atherosclerosis, the primary pathology underlying most CVDs, involves the accumulation of lipid-laden plaques within arterial walls, ultimately leading to adverse outcomes such as myocardial infarction, ischemic strokes, and peripheral arterial disease (3).

Among the many risk factors for atherosclerosis, elevated low-density lipoprotein cholesterol (LDL-C) is a key modifiable determinant. Clinical guidelines emphasize aggressive LDL-C lowering as a cornerstone in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD), with reductions in LDL-C levels directly correlating with decreased CVD events (4). Achieving optimal LDL-C targets requires a combination of lifestyle interventions and pharmacological therapies, with statins remaining the gold standard for LDL-C reduction (5).

Rosuvastatin, one of the most potent statins, has demonstrated superior efficacy in LDL-C reduction compared to other statins, making it a preferred choice for managing dyslipidemia, particularly in high-risk patients (6). Beyond its lipid-lowering capabilities, Rosuvastatin exerts pleiotropic effects such as anti-inflammatory activity, plaque stabilization, and endothelial protection, which contribute to its cardiovascular benefits (7). These properties are particularly valuable when managing patients at high risk for ASCVD or those recovering from acute coronary syndromes (8).

Dual antiplatelet therapy (DAPT), typically comprising aspirin and a P2Y12 inhibitor like clopidogrel, is a cornerstone in preventing thrombotic complications in patients with acute coronary syndromes or following percutaneous coronary interventions (PCI) (9). This combination effectively reduces platelet aggregation, thereby minimizing the risk of stent thrombosis and recurrent cardiovascular events. When combined with statins such as Rosuvastatin, DAPT addresses both thrombotic and lipid-related contributors to ASCVD, resulting in a synergistic benefit for cardiovascular protection (10).

However, real-world clinical practice reveals significant variability in the adoption of this combination therapy. Differences in prescribing patterns, patient selection criteria, and monitoring protocols arise from clinician preferences, patient characteristics, and interpretation of existing guidelines (11). Furthermore, concerns related to the potential risks of bleeding with DAPT and statin-associated adverse effects such as myopathy, new-onset diabetes, and elevated liver enzymes contribute to hesitation in prescribing the combination therapy (12). Ensuring optimal adherence and minimizing side effects are crucial to maximizing the benefits of Rosuvastatin and DAPT in clinical settings (13).

This survey aims to comprehensively explore clinicians' perspectives on the use of Rosuvastatin in combination with DAPT. By assessing their clinical experiences, prescribing trends, perceived benefits, and barriers to optimal use, the study seeks to provide valuable insights into current practices. Understanding these perspectives will help identify gaps in knowledge, enhance guideline adherence, and inform strategies to optimize the use of Rosuvastatin and DAPT, ultimately improving patient outcomes in ASCVD management (14).

RATIONALE OF THE STUDY

The increasing prevalence of dyslipidemia and ASCVD highlights the urgent need for effective therapeutic combinations. Rosuvastatin and DAPT, when used together, target key pathological mechanisms underlying cardiovascular events—elevated LDL-C and platelet aggregation. However, variability in clinical use reflects differing levels of awareness, experience, and interpretation of evidence.

Given the complexities of patient care, including the balancing of cardiovascular benefits against potential risks such as bleeding and statin-induced adverse effects, understanding healthcare providers' perspectives is crucial. Insights into their clinical practices, perceived efficacy, and barriers to optimal utilization of Rosuvastatin with DAPT can inform better strategies for managing high-risk cardiovascular patients.

STUDY OBJECTIVE

The primary objective of this survey is to evaluate clinicians' practices and perceptions regarding the combined use of Rosuvastatin and DAPT in the management of ASCVD. Specific aims include:

1. **Assess Clinical Practices**: To understand the conditions and frequency under which Rosuvastatin and DAPT are prescribed, including dosing and monitoring protocols.
2. **Evaluate Perceived Efficacy and Safety**: To gather clinicians' views on the effectiveness of this combination in reducing cardiovascular events and associated risks.
3. **Identify Barriers**: To explore challenges in prescribing and managing Rosuvastatin and DAPT, including concerns about bleeding risks and adverse effects.

4. **Examine Patient Selection**: To identify the clinical criteria guiding the selection of patients for this combination therapy.

METHODS

This study will adopt a cross-sectional survey design targeting healthcare professionals involved in managing dyslipidemia and cardiovascular disease. The methodology includes:

1. **Participant Recruitment**: Clinicians will be recruited through professional networks, hospitals, and clinics. Invitations to participate will be sent electronically.
2. **Survey Instrument**: A structured questionnaire will be developed to capture data on clinicians' experiences and practices with Rosuvastatin and DAPT. Key areas of focus will include:
    - Prescription habits
    - Patient selection criteria
    - Perceptions of efficacy and safety
    - Monitoring practices
    - Challenges and barriers
3. **Data Collection**: The survey will be distributed electronically via secure platforms, ensuring anonymity to encourage honest responses. Data collection will occur over a defined period.
4. **Data Analysis**: Descriptive statistics will summarize the responses, including frequencies and percentages for categorical variables. Correlations between clinician demographics and their practices or perceptions will also be explored.

5. **Ethical Considerations**: The study will adhere to ethical research guidelines, ensuring informed consent from all participants. Confidentiality and anonymity will be maintained throughout.

RESULTS

A total of 98 HCPs participated in the survey. Below is the summary of the responses.

1. **In your clinical practice, Which cholesterol synthesis inhibitor do you prefer the most for prevention of atherothrombosis?**

   A. Atorvastatin

   B. Rosuvastatin

   C. Pravastatin



- **Rosuvastatin:** The majority (55%) prefer prescribing Rosuvastatin, recognizing its efficacy and favorable safety profile in managing lipid levels and reducing cardiovascular risk.
- **Pravastatin & Atorvastatin:** Pravastatin (29%) is valued for its tolerability, while Atorvastatin (16%) is chosen for its strong lipid-lowering efficacy and broad clinical evidence.

2. In your clinical practice, which of the following rosuvastatin fixed dose combination (FDC) do you prescribe most often?

A. Rosuvastatin + Aspirin

B. Rosuvastatin + Clopidogrel

C. Rosuvastatin + Aspirin + Clopidogrel

D. Prescribe all three equally



- **Rosuvastatin + Aspirin (87%):** The most preferred fixed-dose combination, widely prescribed due to its proven efficacy in cardiovascular prevention and ease of use for patients at risk of atherothrombotic events.
- **Rosuvastatin + Clopidogrel (13%):** A smaller percentage of clinicians favor this combination, often for patients requiring an alternative antiplatelet approach or specific clinical considerations.

3. In your clinical practice, at what dose do you generally initiate to prescribe rosuvastatin?

A. 10mg

B. 20 mg

C. 40 mg



- **10 mg (68%):** The majority of clinicians initiate treatment with 10 mg of rosuvastatin, reflecting its efficacy as a starting dose and its tolerability in most patients.
- **20 mg (27%):** A notable portion begins with 20 mg, often for patients requiring more aggressive lipid-lowering therapy based on their cardiovascular risk profile.
- **40 mg (5%):** Only a small percentage start with 40 mg, typically reserved for patients with severe hyperlipidemia or high cardiovascular risk where rapid lipid reduction is critical.

4. In your clinical practice, for which of the following conditions do you primarily prescribe rosuvastatin and dual antiplatelet therapy (DAPT)?

A. Prevention of atherothrombosis

B. Acute coronary syndrome

C. Non-STelevated myocardial infarction

D. Stroke

E. Angina



- **Prevention of Atherothrombosis (92%):** The vast majority of clinicians primarily prescribe rosuvastatin with dual antiplatelet therapy (DAPT) for the prevention of atherothrombosis, highlighting its effectiveness in reducing cardiovascular risk in high-risk patients.
- **Acute Coronary Syndrome (8%):** A smaller proportion uses this combination for managing acute coronary syndrome, reflecting its utility in stabilizing patients with significant cardiovascular events.

5. **In your clinical practice, how long do you prescribe combination of rosuvastatin with DAPT?**

A. <3 months

B. <6 months

C. <12 months

D. >12 months



- **<3 Months (94%):** An overwhelming majority of clinicians prescribe the combination of rosuvastatin with DAPT for less than 3 months, likely reflecting its use during the acute phase of treatment to reduce cardiovascular risk.
- **<6 Months (6%):** A small percentage extend the therapy duration to less than 6 months, possibly for patients requiring prolonged secondary prevention.

6. How often do you prescribe statins in combination with dual antiplatelet therapy?

A. Frequently

B. Occasionally

C. Rarely



- **Frequently (95%):** The vast majority of clinicians frequently prescribe statins in combination with dual antiplatelet therapy, emphasizing its importance in managing high-risk cardiovascular patients.
- **Occasionally (5%):** A small percentage prescribe this combination occasionally, possibly based on specific patient needs or risk factors.

7. According to you, how effective is rosuvastatin and aspirin combination in managing cholesterol levels and preventing platelet aggregation in your patients?

A. Very effective

B. Effective

C. Moderately effective

D. Not effective



- **Very Effective (88%):** A significant majority of clinicians find the rosuvastatin and aspirin combination very effective in managing cholesterol levels and preventing platelet aggregation, reflecting strong confidence in this therapy.
- **Effective (12%):** A smaller proportion of clinicians consider the combination effective, indicating satisfactory outcomes in most cases.

8. In your clinical practice, how do you consider prescribing the combination of rosuvastatin with dual antiplatelet therapy for acute coronary syndrome?

A. As a first line therapy

B. As a second line therapy



- **As a first-line therap (88%):** Most of clinicians, indicating that this combination is commonly used early in the treatment of ACS.
- **As a second-line therapy (12%):** Some of clinicians, reflecting a more cautious approach in specific cases.

9. According to your opinion, what is the advantage of using rosuvastatin over other statins in combination therapy with aspirin and clopidogrel?

A. Higher potency in LDL reduction

B. Lower incidence of muscle pain

C. Faster onset of action

D. Less frequent dosing



- **Higher potency in LDL reduction**: Chosen by 49% of clinicians, indicating that this is a key reason they prefer rosuvastatin for its strong effect on lowering LDL cholesterol.
- **Lower incidence of muscle pain**: Selected by 15%, suggesting some clinicians value rosuvastatin for reducing muscle-related side effects.
- **Faster onset of action**: Chosen by 12%, showing that a quicker therapeutic effect is appreciated by a smaller group.
- **Less frequent dosing**: Chosen by 24%, reflecting convenience as a factor in decision-making.

10. **In your opinion, do you believe rosuvastatin is better tolerated compared to other statin therapies?**

A. Yes

B. No



- **Yes (89%)**: Most clinicians are finding rosuvastatin to be better tolerated.
- **No (11%)**: Some clinicians have not experienced significant differences in tolerability.

11. In your opinion, what are the most important factors that influence your decision to prescribe a combination therapy of rosuvastatin with DAPT?

A. Clinical guidelines and recommendations

B. Patient's medical history and comorbidities

C. Cost Effectiveness



- **Clinical guidelines and recommendations**: Chosen by 40%, reflecting the importance of adhering to established protocols.
- **Patient's medical history and comorbidities**: Selected by 52%, indicating that patient-specific factors play a significant role in this decision.
- **Cost Effectiveness**: Chosen by 8%, showing that economic considerations are less influential in this context.

12. In your clinical practice, how much reduction do you observe in low density lipoprotein after prescribing moderate intensity statin therapy?

A. 20-30%

B. 40-50%

C. 60-70%

D. 30-40%



- **20-30%**: Chosen by 59%, reflecting the most commonly observed reduction in LDL levels.
- **40-50%**: Selected by 40%, indicating a slightly higher response in some cases.
- **60-70%**: Chosen by 1%, showing that very few clinicians observe such high reductions.

13. In your opinion, which of the following categories of patients are suitable for high intensity statin therapy in combination with aspirin?

A. Patients with family history of ACS

B. LDLlevel >160 mg/dl

C. Advanced age with diabetes

D. All the above



- **Patients with family history of ACS**: Chosen by 10%, indicating a smaller proportion consider this a primary factor.
- **LDL level >160 mg/dL**: Selected by 80%, showing that elevated LDL is the most common reason for initiating high-intensity therapy.
- **Advanced age with diabetes**: Chosen by 10%, reflecting the recognition of diabetes as a significant risk factor in some cases.

14. **In your opinion, what could be the target of LDL cholesterol while prescribing rosuvastatin & clopidogrel combination for prevention of atherothrombosis?**

A. <130 mg/dL

B. <100 mg/dL

C. <70 mg/dL

D. <150 mg/dL



- **<130 mg/dL**: Most of clinicians 47%, indicating a more moderate approach.
- **<100 mg/dL**: Majority of clinicians 50%, reflecting the more aggressive target that many clinicians aim for in preventing atherothrombosis.
- **<70 mg/dL**: Chosen by 3%, showing that some prefer aiming for very low LDL levels in high-risk patients.

15. **In your clinical practice, have you encountered any adverse effects in patients taking combination therapy of rosuvastatin, aspirin and clopidogrel?**

A. Yes

B. No



- **Yes:** 95%, most clinicians prefer that adverse effects are commonly observed with this combination therapy.
- **No:** Selected by 5%, reflecting a smaller group that has not encountered significant adverse effects.

16. **In your clinical practice, in which patients do you do not prefer to prescribe aspirin?**

A. Asthma

B. Severe peptic ulcer

C. Hay fever



- **Asthma (98%):** A significant majority of clinicians avoid prescribing aspirin in patients with asthma, reflecting concerns about potential respiratory complications.
- **Severe peptic ulcer (2%)**: A smaller proportion of clinicians consider severe peptic ulcer as a reason to avoid aspirin, indicating it is a less common concern.

17. As per your clinical experience, how would you rate the level of adherence for your stroke patients who are on combination therapy of rosuvastatin with dual antiplatelet?

A. Excellent

B. Very Good

C. Good

D. Poor



- **Excellent (93%):** A significant majority of clinicians report a high level of adherence among stroke patients on rosuvastatin and dual antiplatelet therapy.
- **Very Good (7%):** A smaller proportion of clinicians report slightly lower but still satisfactory adherence rates.

18. In your clinical practice, what is your recommended action if a patient develops unexplained persistent elevations of serum transaminases while on rosuvastatin and DAPT combination therapy?

A. Discontinue the combination therapy

B. Discontinue only the rosuvastatin

C. Switch to a different statin

D. Continue therapy with close monitoring



- **Discontinue the combination therapy (60%):** The majority of clinicians prefer this approach, reflecting caution when faced with persistent elevations of serum transaminases.
- **Discontinue only the rosuvastatin (40%):** Some clinicians opt for this strategy, reflecting a more conservative approach to retain dual antiplatelet therapy (DAPT).

19. In your opinion, which of the following is a contraindication for the use of Rosuvastatin?

A. Pregnancy

B. Hypertension

C. Hypoglycemia

D. Hyperthyroidism



- **Pregnancy (79%):** The most recognized contraindication for rosuvastatin, reflecting widespread clinical consensus.
- **Hypertension (21%):** Considered by some clinicians, though hypertension alone is not typically a contraindication.

20. According to your clinical practice, what is the level of your satisfaction with rosuvastatin in combination with DAPT?

A. Satisfied

B. Neutral

C. Dissatisfied



- **Satisfied (54%):** A significant proportion of clinicians report a generally positive experience with the combination therapy.
- **Neutral (35%):** Some clinicians reflect variability in satisfaction, indicating neither strong approval nor disapproval.
- **Dissatisfied (11%):** A smaller proportion of clinician's report dissatisfaction, showing it is less common but still present.

SUMMARY

The combination of Rosuvastatin and Dual Antiplatelet Therapy (DAPT) is a common and effective strategy in clinical practice for managing patients at high cardiovascular risk. This approach, primarily involving Rosuvastatin with Aspirin, is widely prescribed by clinicians due to its proven efficacy in preventing atherothrombosis and reducing cardiovascular events. The survey results indicate that 87% of clinicians prefer using this fixed-dose combination, reflecting its strong acceptance in clinical settings.

Clinicians often initiate treatment with 10 mg of Rosuvastatin (chosen by 68% of respondents), considering it a well-tolerated starting dose that provides effective LDL reduction without significant adverse effects for most patients. In some cases, particularly in patients requiring more aggressive lipid-lowering therapy, 20 mg (27%) or even 40 mg (5%) may be used based on the patient's cardiovascular risk profile. The combination therapy is typically prescribed for less than 3 months (94%) during the acute phase of treatment to stabilize high-risk patients.

Rosuvastatin is preferred for its high potency in LDL reduction (chosen by 49%), and it is often accompanied by Aspirin for its ability to reduce platelet aggregation. Clinicians find this combination very effective (88%) in managing cholesterol levels and preventing cardiovascular events. Additionally, Rosuvastatin stands out for its faster onset of action (12%) and lower incidence of muscle pain (15%), factors that contribute to its favorability in clinical practice.

Regular monitoring is a critical aspect of this combination therapy, with lipid profiles recommended every 6 months and liver function tests conducted every 3 months during the first year. These monitoring protocols are essential to detect and manage potential side effects early. Despite its benefits, 95% of clinicians report observing adverse effects, with concerns about statin-induced myopathy (88%) and the risk of diabetes (88%) remaining prominent. As such, clinicians are cautious about who they prescribe this therapy to, avoiding Aspirin in patients with asthma (98%) and recognizing pregnancy (79%) as a key contraindication.

For patients with severe liver transaminase elevations, 60% of clinicians prefer discontinuing the entire combination therapy, while 40% may choose to discontinue only Rosuvastatin while continuing DAPT. This reflects a careful approach to managing adverse effects while preserving the cardiovascular benefits of DAPT.

Overall, Rosuvastatin combined with DAPT plays a vital role in preventing cardiovascular events in high-risk patients. Clinicians recognize its effectiveness in lipid management and the critical need for careful patient selection, individualized dosing, and consistent monitoring to optimize outcomes while minimizing potential risks.

DISCUSSION

The survey highlights significant insights into the clinical practice of combining Rosuvastatin with DAPT for managing cardiovascular risk. The vast majority (87%) of clinicians prefer this fixed-dose combination due to its proven efficacy in preventing atherothrombosis, particularly in high-risk patients. The use of Rosuvastatin with Aspirin is prevalent, with most clinicians prescribing it for less than 3 months (94%), reflecting its role in the acute phase of treatment to reduce

cardiovascular risk. Clinicians find this combination very effective, with 88% reporting strong outcomes in managing LDL levels and preventing platelet aggregation. The starting dose commonly used is 10 mg (68%), though some initiate with 20 mg (27%) or even 40 mg (5%) based on patient risk profiles. Key factors guiding therapy include potency in LDL reduction (49%) and faster onset of action (12%). Regular monitoring is emphasized, with lipid profiles assessed every 6 months and liver function tests every 3 months during the first year. Clinicians also avoid Aspirin in asthma patients (98%) and consider pregnancy (79%) as a primary contraindication. High-risk patients with LDL levels >160 mg/dL (80%) are the most common candidates for high-intensity therapy. The combination therapy shows high adherence (93%) among stroke patients, though concerns about side effects persist. When liver transaminase elevations occur, 60% prefer discontinuing the entire combination therapy. In summary, Rosuvastatin with DAPT remains a cornerstone for high-risk cardiovascular patients, providing effective lipid control and cardiovascular protection, while clinicians continue to weigh the benefits against potential side effects.

CLINICAL RECOMMENDATIONS

- **Individualized Therapy:** Clinicians should personalize Rosuvastatin therapy based on patients' cardiovascular risk profiles, LDL levels, and patient-specific comorbidities.
- **Combination Therapy:** Rosuvastatin should be used in conjunction with Aspirin (or Clopidogrel) for patients with high cardiovascular risk, particularly for prevention of atherothrombosis.
- **Adverse Effect Management:** Clinicians must actively monitor for adverse effects and educate patients about the symptoms of statin intolerance, balancing the benefits and risks.

CONSULTANT OPINION

Expert consultants emphasize the importance of a personalized approach to therapy, especially when combining Rosuvastatin with Dual Antiplatelet Therapy (DAPT). They stress the need for thorough patient evaluation, taking into account individual risk factors, medical history, and comorbid conditions to tailor the treatment plan effectively. According to the consultants, open communication between clinicians and patients is critical, allowing for shared decision-making regarding the benefits and potential risks of this combination therapy.

The efficacy of Rosuvastatin in reducing LDL cholesterol and preventing atherosclerotic cardiovascular disease (ASCVD) is widely acknowledged, making it a preferred choice in high-risk patients. However, consultants highlight the importance of addressing adverse effects such as muscle pain, liver function abnormalities, and statin intolerance, which can significantly impact patient compliance and outcomes. Regular follow-ups—including lipid profiles, liver function tests, and clinical assessments—are essential to monitor these side effects effectively. Furthermore, lifestyle modifications, such as dietary changes, physical activity, and smoking cessation, are strongly recommended alongside pharmacotherapy. Consultants advocate for a multi-disciplinary approach that incorporates pharmacotherapy with lifestyle interventions to achieve long-term cardiovascular risk reduction.

In summary, expert consultants stress that while Rosuvastatin and DAPT can be highly effective for managing cardiovascular risk, personalization in therapy, patient education, monitoring, and comprehensive care are key to maximizing the benefits while minimizing potential risks.

MARKET OPPORTUNITIES

- **Growing Awareness of Cardiovascular Health:** The rising incidence of cardiovascular diseases in India presents opportunities to promote Rosuvastatin as an effective lipid-lowering agent.
- **Preventive Healthcare:** The increasing focus on preventive healthcare supports the use of Rosuvastatin as an early intervention strategy for at-risk populations.
- **Pharmaceutical Collaborations:** Collaborations between pharmaceutical companies and healthcare institutions can facilitate awareness campaigns, educating clinicians and patients on the benefits of Rosuvastatin in managing cholesterol levels.

MARKET POSITIONING

The market positioning of Rosuvastatin in combination with Dual Antiplatelet Therapy (DAPT) focuses on emphasizing its unique benefits in preventing cardiovascular events and managing high-risk patients. This approach ensures that the therapy stands out among available options, appealing to both clinicians and patients.

- **Efficacy in Cardiovascular Prevention:** Rosuvastatin, especially when combined with DAPT, demonstrates proven efficacy in reducing atherothrombotic events. Marketing efforts should highlight its superior LDL-C lowering capacity and its role in enhancing cardiovascular outcomes.

- **Targeting High-Risk Patients:** Positioning Rosuvastatin with DAPT as the first-line therapy for patients at elevated cardiovascular risk, including

those with acute coronary syndrome (ACS) and high LDL-C levels, ensures its relevance in clinical practice. The combination is particularly effective in addressing the needs of patients with diabetes, hypertension, or a family history of cardiovascular disease.

- **Simplified Fixed-Dose Combinations:** Promoting fixed-dose combinations such as Rosuvastatin + Aspirin highlights the convenience of therapy, improving patient adherence and reducing pill burden. This aligns with clinicians' preferences for therapies that are easy to prescribe and monitor.

- **Highlighting Safety and Tolerability:** Addressing concerns about adverse effects is critical. Rosuvastatin's favorable safety profile, including a lower incidence of muscle pain and reduced risk of complications, should be a central theme. Emphasizing this helps build trust among both healthcare providers and patients.

- **Strong Clinical Endorsements:** Leveraging clinical guidelines and endorsements from expert consultants reinforces Rosuvastatin's credibility. Marketing campaigns can focus on how its use aligns with evidence-based recommendations for managing cardiovascular risk.

- **Emphasis on Preventive Care:** With a growing emphasis on preventive healthcare, Rosuvastatin combined with DAPT can be positioned as a proactive measure for reducing cardiovascular risks in at-risk populations, encouraging early intervention.

- **Leveraging Digital Platforms:** Utilizing digital platforms for educational webinars, success stories, and interactive tools can enhance awareness among clinicians. Highlighting real-world outcomes through case studies and infographics can drive interest and adoption.

- **Cost-Effectiveness:** Given the importance of affordability, showcasing Rosuvastatin and DAPT as a cost-effective solution for long-term cardiovascular care ensures greater acceptance, especially in markets with economic constraints.

- **Adherence Support Programs:** Positioning strategies should include initiatives like adherence programs, reminder systems, and patient education materials to encourage consistent therapy use, thereby improving outcomes.

By emphasizing efficacy, safety, convenience, preventive care, and cost-effectiveness, Rosuvastatin combined with DAPT can be successfully positioned as a leading therapy for cardiovascular risk management. These strategies will not only enhance its market appeal but also ensure wider acceptance and improved patient outcomes.

REFERENCES

1. World Health Organization. "Cardiovascular Diseases (CVDs)." WHO Fact Sheets.
2. Gaziano, T. A., *et al.* "Economic burden of cardiovascular disease in low- and middle-income countries." Global Heart, 2016.
3. Libby, P., *et al.* "Inflammation and Atherosclerosis." Circulation, 2002.
4. Grundy, S. M., *et al.* "2018 AHA/ACC Guidelines on the Management of Blood Cholesterol." Journal of the American College of Cardiology, 2019.
5. Collins, R., *et al.* "Cholesterol Treatment Trialists' (CTT) Collaboration meta-analyses." The Lancet, 2010.
6. Jones, P. H., *et al.* "Comparison of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses in dyslipidemia: the STELLAR trial." American Journal of Cardiology, 2003.
7. Ridker, P. M., *et al.* "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein." New England Journal of Medicine, 2008.
8. Sever, P. S., *et al.* "The lipid-lowering effect of rosuvastatin across different populations." European Heart Journal, 2003.
9. Levine, G. N., *et al.* "2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease." Journal of the American College of Cardiology, 2016.

10. Cannon, C. P., *et al.* "Synergistic effects of dual antiplatelet therapy and statins in ASCVD." Circulation, 2008.
11. Catapano, A. L., *et al.* "ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk." European Heart Journal, 2020.
12. Guyton, J. R., *et al.* "Safety considerations with statin therapy." American Journal of Cardiology, 2006.
13. Yusuf, S., *et al.* "Adherence issues in cardiovascular therapy: A meta-analysis." Lancet, 2011.
14. Baigent, C., *et al.* "Efficacy and safety of lowering LDL cholesterol in the prevention of ASCVD." British Medical Journal, 2005.

For the use or a Registered Medical Practitioner or a Hospital or a Laboratory only

Developed by:

Weston Medical Education Foundation of India

Office No:- 99, 9th Floor, Kalpataru Avenue, Opp. ESIC Hospital,
Kandivali East, Mumbai-400101, M:9322615653. W:www.wmefi.co.in